Pomalidomide based drugs: price, availability and description

Pomalidomide is an immunomodulatory agent structurally related to thalidomide. It exhibits antitumor activity by inhibiting the proliferation of malignant cells and blocking angiogenesis (tumor blood vessel growth). Pomalidomide is primarily indicated for the treatment of relapsed and refractory multiple myeloma in patients who have previously received lenalidomide and bortezomib, as well as for Kaposi sarcoma.